Proceed
- Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug product.
- PsiGAD2, short for Psilocybin for Generalised Anxiety Disorder trial two, follows the PsiGAD1 proof of concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Sacle (HAM-A) score from baseline in the psilocybin treatment group.
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
50,000 shares traded pre market so far. Bouncing around a bit but up 10% atm. Let’s see how this goes today
- Forums
- ASX - By Stock
- General discussion
Proceed -Approval from FDA to proceed with 94 patient Phase 2...
-
- There are more pages in this discussion • 357 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)